

## Special Issue

# Clinical Advances in Thyroid Cancer: Biomarker-Driven Diagnosis, Oncogenesis Insights, and Translational Therapies

### Message from the Guest Editor

Thyroid cancer is one of the most common endocrine malignancies, and its diagnosis and management have seen significant advancements in recent years. However, distinguishing between benign and malignant thyroid nodules remains a clinical challenge, particularly in fine-needle aspiration (FNA) samples. The identification of highly sensitive and specific molecular biomarkers, such as the novel oncoprotein Enigma, has the potential to revolutionize the precision of thyroid cancer diagnosis. Additionally, understanding the molecular mechanisms driving thyroid cancer oncogenesis is critical for developing targeted therapies and improving patient outcomes. This Special Issue aims to highlight the latest research in molecular biomarker discovery, oncogenic pathways, and the translation of these findings into clinical practice.

### Guest Editor

Dr. Salma Khan

1. Division of Biochemistry, Loma Linda University School of Medicine, Loma Linda, CA, USA
2. Center for Health Disparities & Molecular Medicine, Loma Linda University, Loma Linda, CA, USA

### Deadline for manuscript submissions

31 December 2025



## Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 4.9  
Indexed in PubMed



[mdpi.com/si/234722](https://mdpi.com/si/234722)

*Current Oncology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)

[mdpi.com/journal/  
currentoncology](https://mdpi.com/journal/currentoncology)





# Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 4.9  
Indexed in PubMed



[mdpi.com/journal/  
currentcol](https://mdpi.com/journal/currentcol)



## About the Journal

### Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

---

### Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada
  2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada
- 

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology)